FDA Approves Expanded Label for Dapagliflozin to Reduce Risk of Cardiovascular Death, Hospitalization from Heart Failure The FDA has approved an expanded label for dapagliflozin (Farxiga; AstraZeneca) to include an indication to reduce the risk of cardiovascular (CV) death, hospitalization for heart failure (HF), and urgent HF in adults. blacksalmon – stock.adobe.com The approval for […]

Negotiations between the pharmaceutical industry, Government and NHS England around a new branded medicines pricing scheme began yesterday (May 4). The medicines industry was represented by the Association of the British Pharmaceutical Industry (ABPI) at the initial meeting to discuss a successor to the voluntary scheme for branded medicines, pricing and access (VPAS). A joint […]